Kybella®

The First and Only FDA-approved Injectable Treatment for "Double Chin" Recognized as "2015 Breakthrough" at Allure Awards Ceremony DUBLIN, Oct. 2, 2015 /PRNewswire/ -- Allergan, plc (NYSE: AGN) is pleased to announce that KYBELLA® (deoxycholic acid) injection, the first and only FDA-approved injectable treatment for improving the appearance of moderate to severe submental fullness, also known as "double chin," received a "2015 Breakthrough Award" from Allure Magazine. The publication honored KYBELLA®, along with other winners from their annual "Best of Beauty" list, which included hundreds of luxury, mass market and specialty beauty and aesthetic brands, on September 21 at an awards ceremony held at One World Trade Center in New York.

Los Angeles Kybella

The active ingredient in KYBELLA® is synthetic deoxycholic acid. Deoxycholic acid is a naturally occurring molecule in the body that aids in the breakdown and absorption of dietary fat. When injected into the fat beneath the chin, KYBELLA® destroys fat cells, resulting in a noticeable reduction in fullness under the chin. Once destroyed, these cells can no longer store or accumulate fat, so further treatment is not expected once you reach your desired aesthetic goal.